SHERIDAN, WYOMING – July 29, 2025 – Bio-Rad Laboratories has named Rajat Mehta as its new Executive Vice President of Global Commercial Operations, signaling a strategic push to accelerate growth across its diagnostics and life sciences business lines. Mehta, whose appointment takes effect August 4, 2025, brings broad cross-sector expertise and a proven track record of commercial execution in the biopharma and scientific instrumentation industries.
New commercial leadership aimed at scaling global market impact
With over two decades of experience spanning Labcorp, Thermo Fisher Scientific, and Dow Chemical, Mehta is positioned to enhance Bio-Rad’s commercial alignment across geographies and market verticals. His appointment follows the planned retirement of industry veteran Mike Crowley, who has served in senior roles at Bio-Rad since 1998 and helped shape its global sales infrastructure over the past decade.
“Rajat's proven track record in delivering above-market growth, building high-achieving teams, and driving alignment across multiple business segments will be instrumental as we continue to advance our long-term strategy,” said Jon DiVincenzo, Bio-Rad’s President and Chief Operating Officer.
Enhancing commercial operations across diagnostics and research
As EVP, Mehta will lead the company’s commercial execution strategy, spanning clinical diagnostics, life sciences research, and specialized laboratory markets. His previous leadership at Labcorp’s West Division and Thermo Fisher’s Applied Technologies unit saw him drive growth across enterprise-scale business units, integrating customer needs with scalable commercial frameworks.
Key areas where Mehta is expected to make an immediate impact include:
- Optimizing go-to-market execution across global regions
- Enhancing commercial performance through data-driven analytics
- Driving cross-functional collaboration between sales, service, and marketing
- Aligning channel strategies with emerging biopharma and translational research needs
Strategic timing amid industry transformation
Mehta’s appointment comes as the life science tools and diagnostics sector faces mounting pressure to deliver precision, speed, and scalability in a post-pandemic research landscape. From regulatory scrutiny in clinical testing to the rise of AI-driven workflows, the demand for adaptable commercial leadership is high.
Bio-Rad, with $2.6 billion in 2024 revenues and a workforce of approximately 7,500, is navigating this transformation by reinforcing its leadership team and scaling its presence in high-impact segments such as clinical informatics, molecular diagnostics, and environmental testing.
Acknowledging legacy leadership and continuity
Norman Schwartz, Chairman and CEO of Bio-Rad, emphasized the company’s gratitude to outgoing EVP Mike Crowley for more than two decades of service:
“On behalf of everyone at Bio-Rad, I want to extend our deepest gratitude and acknowledgement to Mike Crowley for his exceptional service and unwavering dedication. Since joining our commercial team in 1998, and particularly during his tenure as EVP of Global Commercial Operations since 2014, Mike’s leadership has been instrumental in building our global sales and services organization and contributing to Bio-Rad’s overall success.”
Positioning Bio-Rad for sustained competitive advantage
The strategic leadership transition is aligned with Bio-Rad’s long-term focus on commercial excellence, innovation deployment, and operational scalability. With Mehta at the helm of global commercial operations, the company is expected to sharpen its market responsiveness and unlock new growth across diagnostics and applied life science sectors.
Learn more about Bio-Rad’s leadership and solutions at www.bio-rad.com